• We need a postmarketing drug development process!
  We need a postmarketing drug development process!

  Pharmacoepidemiol Drug Saf. 2000 May ;9(3):253-5.
  PubMed
• Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a...
  Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.

  Mov Disord. 2009 Jan 30 ;24(2):277-82.
  PubMed
• Human brain prostaglandin D synthase has been evolutionarily differentiated from...
  Human brain prostaglandin D synthase has been evolutionarily differentiated from lipophilic-ligand carrier proteins.

  Proc Natl Acad Sci U S A. 1991 May 1 ;88(9):4020-4.
  PubMed
• Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkin...
  Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.

  J Neurosci Res. 2009 May 1 ;87(6):1283-95.
  PubMed
• Guanine nucleotide-binding regulatory proteins in retinal pigment epithelial cel...
  Guanine nucleotide-binding regulatory proteins in retinal pigment epithelial cells.

  Proc Natl Acad Sci U S A. 1991 May 1 ;88(9):3907-11.
  PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on